尼妥珠单抗致嗅觉丧失  

Anosmia induced by nimotuzumab

作　　者：费小非[1] 李馨艳[1] 郑鹿[1] 

机构地区：[1]中国医学科学院北京协和医学院肿瘤医院药剂科,北京100021

出　　处：《药物不良反应杂志》2013年第3期161-162,共2页Adverse Drug Reactions Journal

摘　　要：1例37岁男性患者因Ⅲ期鼻咽癌进行同步放化疗联合尼妥珠单抗靶向治疗,第1、6、41、48天分别静脉滴注尼妥珠单抗200 mg+0.9%氯化钠注射液250 ml;第6~51天行调强放疗;第28天起行2个周期同步化疗(顺铂80 mg/m^2,分2 d静脉滴注,每个周期21 d)。首次静脉滴注尼妥珠单抗后第2天患者诉嗅觉丧失,对所有种类气味均不敏感,持续至第57天患者病情缓解出院。出院后1个月复诊,患者自诉可闻及刺激性气味;6个月复诊,自诉嗅觉部分恢复。A 37-year-old male underwent the synchronal radiochemotherapy combined with nimotuzumab for stage m nasopharyngeal carcinoma. He received an IV infusion of nimotuzumab 200 mg dissoloved in 0. 9% sodium chloride 250 ml on the first, sixth, forty-first, and forty-eighth days, respectively. The intensity-modulated radiation therapy was given from the sixth day to the fifty-first day. Two cycles of the synchronal chemotherapy [ an IV infusion of cisplatin 80 mg/（ m2 · 2 d） , 3 weeks for a cycle ] were given from the twenty-eighth day. The patient reported anosphrasia on the second day after the first IV infusion of nimotuzumab. The symptom of insensitivity to all kinds of smell lasted till the fifty-seventh day when the patient＇s condition was improved and he was discharged. The patient reported that he could smell pungent smell one month after discharge for subsequent visit and his olfactory sensation was partly restored on six month＇s subsequent visit.

关 键 词：尼妥珠单抗 鼻咽癌 嗅觉丧失 

分 类 号：R595.3[医药卫生—内科学]